Pinned Tweet
Replying to @SpicyIP
As we step into the new year, we thank our readers for their continued support and wish everyone a very happy and healthy year ahead.(5/5)
spicyip.com/2025/12/a-look-b…
1
1,022
Can Bangladesh’s deferred LDC graduation help keep life-saving medicines affordable in India? In this post, Maneesha Gupta traces the link between Bangladesh’s TRIPS pharmaceutical exemption... (1/2)
....and Section 107A(b) of the Patents Act, 1970, showing how authorized generic imports can open an access pathway.
spicyip.com/2026/11/what-ban… (2/2)
SpicyIP (spicyip.bsky.social) retweeted
...the Court has now extended the principles of forum conveniens to patent, design and trade secret disputes. In this post, Maneesha Gupta examines the latest ruling.
spicyip.com/2026/11/spicyip-… (2/2)
SpicyIP (spicyip.bsky.social) retweeted
The DHC's recent approach to territorial jurisdiction in IP disputes marks a welcome shift from its traditionally expansive approach to entertaining IP suits. Building on Justice Kaurav’s ruling in ABD Maestro,...(1/2)
In Part I, Dr. Aakanksha Kumar argued that the MHC's order in Saravanan Hari v. Blink Commerce reached the right result without sorting out the claims it was enforcing, and that the plaintiff’s celebrity status is beside the point. Part II looks at the persona...(1/2)
...itself, a superfan figure made from CSK’s and Dhoni’s signs, and at the Blinkit advertisement that borrowed it.
spicyip.com/2026/11/whistle-… (2/2)
A CSK superfan who paints himself yellow and writes Dhoni’s (nick)name and number on his body has won an interim injunction against Blinkit in the Madras High Court. In Part I of this post, Dr. Aakanksha Kumar looks at what the order gets right, where it once again... (1/2)
1
3
401
... blurs the right of publicity with passing off, and why it should not matter whether Saravanan Hari is a “celebrity”.
spicyip.com/2026/11/part-i-w… (2/2)
46
The Patent Office’s rejection of TB Alliance’s patent application for the BPaL tuberculosis drug regimen has been widely welcomed as a win for access to medicines. However, the rather brief rejection order raises some important questions about the quality of reasoning... (1/2)
... in patent adjudication, particularly when claims have undergone substantive amendments during prosecution. In this post, @Gourowski_23 examines the order, the amended claims, and the objections that remain relevant to their patentability.
spicyip.com/2026/11/bitter-s…
The DHC's recent approach to territorial jurisdiction in IP disputes marks a welcome shift from its traditionally expansive approach to entertaining IP suits. Building on Justice Kaurav’s ruling in ABD Maestro,...(1/2)
...the Court has now extended the principles of forum conveniens to patent, design and trade secret disputes. In this post, Maneesha Gupta examines the latest ruling.
spicyip.com/2026/11/spicyip-… (2/2)
Priced at Rs. 2.66 crore, Trikafta remains out of reach for most patients with Cystic Fibrosis in India. Despite repeated appeals by patients and the availability of several safeguards under the Patents Act to address such situations, little has changed. (1/2)
With Vertex’s patent appeal coming up before the Delhi High Court, in this post, Rishabh Upadhyay examines the patent thicket surrounding the drug and the larger failure to secure access to essential medicines. (2/2)
spicyip.com/2026/11/vertex-a…
This week’s Bell of the Week: Public Lab
This week, we look at Public Lab, a community-led initiative that emerged in the aftermath of the Deepwater Horizon oil spill. Through open-source tools, shared research and collaborative documentation, (1/3)
1
142
Public Lab showed how environmental science could become more accessible and participatory. It also offers an interesting perspective on intellectual property: how open licences and shared knowledge can enable people to create, adapt and build upon one another's work. (2/3)
1
33
Alongside this, we have our usual roundup of upcoming events, calls for papers, conferences and other opportunities from across the IP world. Read this week's Bells & Whistles by Gaurangi Kapoor to know more.
spicyip.com/2026/11/spicyip-… (3/3)
22
SpicyIP Weekly Review (November 09-November 15)
After a busy week featuring several interesting and important posts on some pressing questions in Indian IP law and policy, we are back to kick off the week with another edition of the SpicyIP Weekly Review. (1/3)
1
134
This Weekly Review brings together discussions on a range of issues, from the proposed introduction of data exclusivity and its implications for India’s pharmaceutical landscape to the limits of territorial jurisdiction in IP disputes...(2/3)
1
38
...and the evolving contours of personality rights. Anything we missed? Drop a comment on the post and let us know!
spicyip.com/2026/11/spicyip-… (3/3)
26
